Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin
| Autor: | Tilman D. Rachner, Peggy Benad-Mehner, Martina Rauner, Andy Göbel, Lorenz C. Hofbauer, Stefanie Thiele |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
musculoskeletal diseases
animal structures lcsh:Diseases of the musculoskeletal system ER estrogen receptor DEX dexamethasone Bioinformatics RANKL receptor activator of NF-κB ligand lcsh:RC254-282 SDC1 syndecan-1 Syndecan 1 Breast cancer Osteoprotegerin Downregulation and upregulation Osteoclast ACTB β-actin medicine C control biology business.industry PR progesterone receptor medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens carbohydrates (lipids) medicine.anatomical_structure Oncology Proteoglycan OPG osteoprotegerin RANKL Tumor progression embryonic structures biology.protein Cancer research ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 Syndecan-1 lcsh:RC925-935 business GAPDH glyceraldehyde 3-phosphate-dehydrogenase Research Article |
| Zdroj: | Journal of Bone Oncology, Vol 3, Iss 1, Pp 18-24 (2014) Journal of Bone Oncology |
| ISSN: | 2212-1374 |
| Popis: | Background: Breast cancer often metastasizes into bone and leads to osteolytic lesions. The underlying mechanisms, however, are complex and not fully understood. Syndecan-1 is a proteoglycan that has various functions relevant for tumor progression including cell–cell communication and cell–matrix interactions. Moreover, its two glycosaminoglycan-binding sites suggest that it may interfere with glycoproteins such as osteoprotegerin, a potent inhibitor of osteoclastogenesis. Thus, we hypothesize that tumor-derived syndecan-1 alters osteoclast biology by modulating osteoprotegerin. Methods: Syndecan-1 expression was down-regulated via siRNA and the cell fate of the breast cancer cell lines MCF-7, T-47D, and MDA-MB-231 was investigated. Furthermore, we determined the regulation of syndecan-1 by dexamethasone, a commonly used antiemetic in breast cancer therapy. Additionally, we analyzed the genesis and activity of osteoclasts in indirect co-culture experiments using supernatants from MCF-7 cells with deficient and sufficient levels of syndecan-1. Results: Dexamethasone time- and dose-dependently increased syndecan-1 expression up to 4-fold but did not alter cell behavior. Syndecan-1 up-regulation did not affect the survival or migration of breast cancer cells. Depletion of syndecan-1 using siRNA led to decreased vitality of progesterone receptor-positive cell lines. In MCF-7 cells osteoprotegerin production was up-regulated 2.5-fold after syndecan-1 knock-down. The culture of osteoclast precursors with the supernatant of MCF-7 cells with reduced syndecan-1 levels suppressed osteoclast formation and activity by 21% and 23%, respectively. Adding neutralizing antibodies to osteoprotegerin to the breast cancer supernatants reversed osteoclastogenesis. Conclusion: Thus, we identified tumor-derived syndecan-1 as a novel positive regulator of osteoclastogenesis and new player in the tumor-bone dialog. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|